TS 23

Drug Profile

TS 23

Alternative Names: DS-9231; Stromab; TS23

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Translational Sciences
  • Developer Daiichi Sankyo Company; Translational Sciences
  • Class Antithrombotics
  • Mechanism of Action Antiplasmin inhibitors; Fibrinolytic agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Thrombosis

Most Recent Events

  • 01 Dec 2017 Daiichi Sankyo will return the rights for TS 23 to Translational Sciences after phase I trial completion
  • 01 Dec 2017 Phase-I clinical trials in Thrombosis in USA (IV)
  • 01 Dec 2017 Translational Sciences plans clinical trials for Cardiovascular disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top